Director Sangeeta N. Bhatia filed a Form 4 with the SEC on November 18, 2026, disclosing the sale of 271 shares of Vertex Pharmaceuticals common stock on November 16, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals Inc / MA (NASDAQ:VRTX)
  • Shares sold: 271 shares of common stock disposed of on November 16, 2026
  • Sale price: $547.86 per share
  • Remaining holdings: 4,653 shares of common stock held directly following the transaction
  • Trading plan: The sale was made pursuant to a Rule 10b5-1 trading plan entered into on August 13, 2026
  • Transaction code: S (sale)

Vertex Pharmaceuticals Director Bhatia Sells Shares Under 10b5-1 Plan

According to the Form 4 filed on November 18, 2026, Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals Inc / MA (NASDAQ:VRTX), disposed of 271 shares of the company's common stock on November 16, 2026, at a price of $547.86 per share. The filing identifies the transaction code as "S," indicating a sale in the open market.

The filing notes that the transaction was "made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 08/13/2026." The Form 4 also carries a checkbox indicating the transaction was executed under a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the reported sale, the filing discloses that Dr. Bhatia directly held 4,653 shares of Vertex Pharmaceuticals common stock. No derivative securities transactions were reported in Table II of the filing.

The form was signed by Christiana Stevenson as attorney-in-fact on November 18, 2026, and was filed as an individual, single-reporting-person submission. The address of record for the reporting person is listed as c/o Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210.

What Was Disclosed

The filing reports a single open-market sale of 271 shares of Vertex Pharmaceuticals common stock by director Sangeeta N. Bhatia at $547.86 per share on November 16, 2026, executed under a Rule 10b5-1 plan established on August 13, 2026, leaving her with 4,653 directly held shares.